Whitehawk Therapeutics
WHWKWhitehawk Therapeutics is pioneering a new class of oral immunotherapies that target key metabolic enzymes in the tumor microenvironment to overcome immune resistance. The company's platform focuses on modulating the kynurenine pathway, specifically inhibiting TDO2 and IDO1, to restore effective anti-cancer immunity. With its lead candidate, WHK-001, advancing in clinical trials for solid tumors, Whitehawk aims to address significant unmet needs in oncology. The company leverages deep expertise in immuno-oncology and small molecule drug discovery to develop potentially transformative treatments.
WHWK · Stock Price
Historical price data
AI Company Overview
Whitehawk Therapeutics is pioneering a new class of oral immunotherapies that target key metabolic enzymes in the tumor microenvironment to overcome immune resistance. The company's platform focuses on modulating the kynurenine pathway, specifically inhibiting TDO2 and IDO1, to restore effective anti-cancer immunity. With its lead candidate, WHK-001, advancing in clinical trials for solid tumors, Whitehawk aims to address significant unmet needs in oncology. The company leverages deep expertise in immuno-oncology and small molecule drug discovery to develop potentially transformative treatments.
Technology Platform
Platform for discovering oral small molecule inhibitors of immunometabolic enzymes in the tumor microenvironment, with a focus on TDO2 and IDO1 within the kynurenine pathway.
Pipeline
2| Drug | Indication | Stage | Watch |
|---|---|---|---|
| HWK-016, MUCIN-16-targeted ADC + Bevacizumab | PROC | Phase 1 | |
| HWK-007 | Endometrial Cancer | Phase 1 |
Funding History
2Opportunities
Risk Factors
Competitive Landscape
Competes with other biotechs (e.g., Kyn Therapeutics) targeting the TDO2/IDO pathway. Differentiation lies in WHK-001's brain penetration for glioblastoma and its oral administration. Must demonstrate superior efficacy or safety to overcome historical skepticism from prior IDO1 inhibitor failures.